Both companies are in the same sector (Health Care) — compared here on their latest annual financials and current price.
Valuation is about even, Profitability favors Akari Therapeutics Plc, Safety favors Akari Therapeutics Plc. (A relative comparison within the same universe/sector — not a buy/sell recommendation.)
| Dimension | ELI LILLY & Co | Akari Therapeutics Plc |
|---|---|---|
| Valuation | ★☆☆☆☆ | ★☆☆☆☆ |
| Profitability | ★★★★☆ | ★★★★★ |
| Safety | ★☆☆☆☆ | ★★★★★ |
| Growth | ★★★★☆ | – |
| Metric | ELI LILLY & Co | Akari Therapeutics Plc |
|---|---|---|
| P/E | 254.8x | -38124.0x |
| P/B | 93.54x | -3294812.92x |
| ROE% | 36.7% | 8642.4% |
| Op. Margin% | – | – |
| Debt Ratio% | 452% | -12372% |
| Div. Yield% | 0.33% | – |
| Market Cap | $1,335.0B | $754.5B |
| Health Score | 36.7 | 54.1 |
Bold, accent-colored figures mark the better value for that metric. Data: latest SEC filings and current price. Health Score percentiles are computed across the full universe. Not investment advice. ← Back to the screener